DDR1 Antibody

What is DDR1 and why is it a significant target for antibody development?

DDR1 is a receptor tyrosine kinase that binds to and is activated by various types of collagen. It has been identified as a cancer-associated receptor tyrosine kinase that is highly expressed in several malignancies relative to normal tissues . Its cell-surface localization and swift endocytosis characteristics make it an ideal target for antibody-based therapies . DDR1 plays crucial roles in promoting tumor growth, mediating immune exclusion, and contributing to therapy resistance, making it a valuable target for cancer intervention strategies .

How do I select the appropriate DDR1 antibody for my research?

Selection depends on your experimental goals. Consider these factors:

• Target epitope specificity: For functional studies, choose antibodies targeting functionally significant domains. For example, antibodies targeting the DS-like domain (as with PRTH-101) can impact DDR1 activity without directly competing with collagen binding .

• Species cross-reactivity: Verify reactivity with your model system (human, mouse, rat) .

• Application compatibility: Ensure compatibility with your intended techniques (WB, IHC, flow cytometry, etc.) .

• Clonality: Monoclonal antibodies provide consistent specificity for repeated experiments, while polyclonals may offer broader epitope recognition .

• Validation status: Select antibodies validated specifically for your application with published literature support .

What are the optimal protocols for immunohistochemical detection of DDR1 in tissue samples?

For optimal IHC detection of DDR1:

• Tissue preparation: Use paraffin-embedded sections (5μm thickness) with appropriate antigen retrieval. DDR1 detection typically requires heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) .

• Blocking and antibody incubation: After deparaffinization and rehydration, block with 3% hydrogen peroxide (150 min) followed by goat serum blocking (1.5 hours at room temperature). Incubate with anti-DDR1 antibody overnight at 4°C (optimal dilution typically 1:50-1:200 depending on antibody) .

• Detection system: Use HRP-conjugated secondary antibodies (e.g., DakoReal™EnVision™) with 30-minute incubation at room temperature, followed by diaminobenzidine (DAB) visualization .

• Controls: Include positive controls (known DDR1-expressing tissues like colon carcinoma) and negative controls (omitting primary antibody) .

• Scoring system: Implement a standardized scoring system based on staining intensity and percentage of positive cells to ensure reproducibility .

How can I quantify shed DDR1 ECD (extracellular domain) in experimental samples?

A sandwich ELISA approach is most effective:

• Plate preparation: Coat high-binding 96-well plates with capture antibody (5 μg/mL of polyclonal rabbit anti-DDR1) overnight at 4°C .

• Blocking: Block with 3% BSA for 1 hour at room temperature .

• Sample incubation: Add 100 μL of conditioned media containing shed DDR1 and incubate for 1 hour at room temperature with gentle shaking .

• Detection: Use a non-competing biotinylated anti-DDR1 antibody (0.5 μg/mL) that targets a different epitope than your capture antibody, followed by streptavidin-HRP (1:1000 dilution) and appropriate substrate .

• Quantification: Generate a standard curve using recombinant DDR1 ECD of known concentrations for accurate quantification .

This approach allows sensitive detection of shed DDR1 ECD as a biomarker for DDR1 activity in experimental conditions.

How can DDR1 antibodies be employed in developing antibody-drug conjugates (ADCs) for cancer therapy?

Development of anti-DDR1 ADCs involves several critical steps:

• Antibody selection: Choose antibodies with high specificity, strong binding affinity, and rapid internalization properties. The extracellular domain (amino acids 21-417) serves as an effective immunogen for developing therapeutic antibodies .

• Payload selection: Most successful DDR1-ADCs utilize tubulin inhibitors like DM4, which have demonstrated potent anti-proliferative activity in the nanomolar range .

• Conjugation chemistry: Optimize drug-antibody ratio (DAR) typically between 3.5-4.0 for maximum efficacy while maintaining antibody properties .

• Efficacy testing: Evaluate in cell lines with varying DDR1 expression levels. For example, T4H11-DM4 has demonstrated complete tumor regression at doses of 5-10 mg/kg in colorectal cancer models and breast cancer models, with efficacy correlating with DDR1 expression levels .

• Safety profiling: Assess tolerability through multi-dose studies in animal models. Evidence suggests DDR1-targeted ADCs like T4H11-DM4 show no overt toxicities when administered at therapeutic doses .

How do DDR1 antibodies modify the tumor microenvironment and immune responses?

DDR1 antibodies can significantly alter the tumor microenvironment through several mechanisms:

• Disruption of collagen alignment: Therapeutic antibodies like PRTH-101 can disrupt the collagen fiber alignment that DDR1 promotes, thereby reducing the physical barrier that prevents immune cell infiltration .

• Enhancement of T-cell infiltration: Treatment with DDR1-targeting antibodies increases CD8+ T-cell infiltration into tumors, reversing immune exclusion .

• Blocking DDR1 shedding: Certain antibodies (e.g., PRTH-101) prevent DDR1 ECD shedding, which appears to be an important mechanism for modifying the tumor microenvironment .

• Impact on immune checkpoint expression: DDR1 expression positively correlates with immune checkpoint molecules. DDR1 antibodies may therefore indirectly impact immune checkpoint signaling pathways .

• Synergy with immunotherapy: Targeting DDR1 can sensitize microsatellite stable colorectal tumors to PD-1 blockade, suggesting valuable combination approaches .

What are common challenges in generating specific DDR1 antibodies, and how can they be addressed?

Generating highly specific DDR1 antibodies presents several challenges:

• Structural complexity: DDR1 contains multiple domains (DS domain, DS-like domain, transmembrane region, kinase domain). For domain-specific antibodies, use recombinant protein fragments corresponding to specific domains as immunogens .

• Cross-reactivity with DDR2: Due to structural homology between DDR1 and DDR2, careful epitope selection and extensive validation are required. Screen candidates against both proteins to ensure specificity .

• Functional validation: Beyond binding, assess functional activity of antibodies:

  • Inhibition of collagen binding

  • Blocking of phosphorylation

  • Effects on DDR1 shedding

  • Impact on downstream signaling

• Hybridoma instability: During development, multiple rounds of subcloning may be necessary to ensure stable antibody-producing hybridoma lines. After fusion of mouse spleen cells with SP2/0 cells, perform careful screening by ELISA against the immunogen, followed by functional validation on DDR1-expressing cells .

How can researchers validate DDR1 antibody specificity in their experimental systems?

Multi-level validation approaches are essential:

• Genetic validation:

  • Test antibody on DDR1 knockout models or cell lines

  • Utilize DDR1 siRNA knockdown followed by Western blot analysis

  • Express DDR1 in non-expressing cell lines as positive controls

• Epitope mapping:

  • Use synthetic peptides or domain-truncated proteins

  • Employ hydrogen-deuterium exchange mass spectrometry

  • X-ray crystallography for detailed epitope characterization

• Cross-platform confirmation:

  • Concordance between protein (Western blot/IHC) and mRNA expression

  • Multiple antibodies targeting different epitopes should show similar patterns

• Functional validation:

  • Evaluate ability to block DDR1 phosphorylation (Y796)

  • Assess effects on collagen-mediated DDR1 activation

  • Measure impact on downstream signaling events

How can DDR1 antibodies be leveraged to overcome immunotherapy resistance in solid tumors?

Recent research reveals promising strategies:

• Combination therapies: DDR1 antibodies synergize with immune checkpoint inhibitors. This approach has shown particular promise in microsatellite stable colorectal cancer, where DDR1 knockdown or inhibition enhanced CD8+ T cell infiltration and sensitized tumors to PD-1 blockade .

• Targeting ECM remodeling: DDR1 antibodies disrupt collagen fiber alignment, allowing better immune cell infiltration. Treatment of tumor-bearing mice with PRTH-101 reversed immune exclusion by disrupting collagen fibers surrounding tumors, enhancing T cell infiltration .

• Biomarker-guided approaches: DDR1 expression correlates with response to therapies:

  • High DDR1 expression correlates with sorafenib resistance in liver cancer

  • DDR1 levels correlate inversely with CD8+ T cell infiltration

  • DDR1 expression positively correlates with immune checkpoint molecules

• Molecular mechanism targeting: DDR1 antibodies can inhibit specific mechanisms:

  • Preventing DDR1-mediated upregulation of EZH2 and H3K27me3 levels

  • Reversing suppression of chemokine (CXCL10) expression

  • Blocking DDR1 shedding, which appears critical for its immunomodulatory effects

What considerations are important when developing humanized DDR1 antibodies for clinical applications?

Key considerations include:

• Humanization strategy: Complementarity-determining region (CDR) grafting is effective, as demonstrated with PRTH-101. This process maintains the binding affinity and specificity of the parental antibody while reducing immunogenicity .

• Binding epitope selection: Targeting the DS-like domain (as with PRTH-101) rather than the collagen-binding DS domain can provide advantages for certain applications. Crystal structure analysis at 3.15 Å resolution confirmed PRTH-101 binds to the DS-like domain of DDR1, which is distal to the collagen-binding site .

• Functional evaluation:

  • Verify subnanomolar affinity to DDR1 is maintained

  • Confirm inhibition of DDR1 phosphorylation

  • Assess effects on collagen-mediated cell attachment

  • Validate blocking of DDR1 shedding from cell surface

• Effector function considerations: Depending on mechanism of action, consider antibody isotype selection to either enhance or minimize Fc-mediated effects .

• Potential on-target toxicities: Though DDR1 is overexpressed in tumors, careful assessment of normal tissue expression is critical to anticipate potential on-target toxicities .

How does the utility of DDR1 antibodies vary across different cancer types?

DDR1 antibodies show distinct utility across cancer types:

What methodological approaches can be used to study DDR1 antibody-mediated effects on cancer stem cells?

Advanced methodologies include:

• Isolation and characterization:

  • Flow cytometry using anti-DDR1 antibodies to isolate DDR1-high cancer stem cells

  • Sphere formation assays to assess stemness properties

  • Serial transplantation studies in animal models to confirm stem cell properties

• Mechanism investigation:

  • Analysis of collagen cleavage and generation of the 3/4 fragment that activates DDR1

  • Assessment of matrix metalloprotease inhibition in combination with DDR1 antibodies

  • Investigation of DDR1-mediated signaling pathways in stem cells

• Therapeutic evaluation:

  • Combination of DDR1 antibodies with conventional chemotherapy

  • Assessment of tumor recurrence after treatment

  • Analysis of tumor-initiating capacity after DDR1 antibody treatment

• Biomarker development:

  • Correlation of DDR1 expression with stemness markers

  • Development of predictive assays for response to DDR1-targeted therapies

  • Monitoring of circulating DDR1-positive tumor cells as indicators of treatment response